1-4 of 4
David A. Tice
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305

Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, Niall J. Dickinson, Luke Masterson, Thais Cailleau, Ian Hutchinson, Balakumar Vijayakrishnan, Mary McFarlane, Kathryn Ball, Michael Davies, Arthur Lewis, Yue Huang, Anton I. Rosenbaum, Jiaqi Yuan, Jon Chesebrough, Judith Anderton, Noel Monks, Steven Novick, Jixin Wang, Nazzareno Dimasi, R. James Christie, Darrin Sabol, Frances Anne Tosto, Yann Wallez, Elisabetta Leo, Mark R. Albertella, Anna D. Staniszewska, David A. Tice, Philip W. Howard, Nadia Luheshi, Puja Sapra
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1086–1101.
https://doi.org/10.1158/1078-0432.CCR-22-2630
Published: 14 March 2023
View article titled, Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Open the PDF for Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305 in another window
Includes: Supplementary data
Journal Articles

Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

Steven Coats, Marna Williams, Benjamin Kebble, Rakesh Dixit, Leo Tseng, Nai-Shun Yao, David A. Tice, Jean-Charles Soria
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (18): 5441–5448.
https://doi.org/10.1158/1078-0432.CCR-19-0272
Published: 13 September 2019
View article titled, Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
Open the PDF for Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index in another window
Journal Articles

SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads

Krista Kinneer, John Meekin, Arnaud C. Tiberghien, Yu-Tzu Tai, Sandrina Phipps, Christine Mione Kiefer, Marlon C. Rebelatto, Nazzareno Dimasi, Alyssa Moriarty, Kyriakos P. Papadopoulos, Sriram Sridhar, Stephen J. Gregson, Michael J. Wick, Luke Masterson, Kenneth C. Anderson, Ronald Herbst, Philip W. Howard, David A. Tice
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (24): 6570–6582.
https://doi.org/10.1158/1078-0432.CCR-18-1300
Published: 13 December 2018
View article titled, SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Open the PDF for SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads in another window
Includes: Supplementary data
Journal Articles

5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma

Samuel A. Kerk, Kelsey A. Finkel, Alexander T. Pearson, Kristy A. Warner, Zhaocheng Zhang, Felipe Nör, Vivian P. Wagner, Pablo A. Vargas, Max S. Wicha, Elaine M. Hurt, Robert E. Hollingsworth, David A. Tice, Jacques E. Nör
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2516–2527.
https://doi.org/10.1158/1078-0432.CCR-16-1834
Published: 14 May 2017
View article titled, 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma
Open the PDF for 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data